Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy
company, recently announced that it has retained pharmaceutical branding agency
Addison Whitney to assist with the naming of the company’s leading drug
candidate (http://ibn.fm/ci3KJ).
An article further discussing the company reads, “Addison Whitney has a proven
track record of branding success within the pharmaceutical market. It enables
clients to achieve growth through both brand differentiation and creative
naming practices. Its most recent successes include guiding pharmaceutical
companies such as Merck, Celgene and Roche through the regulatory steps needed
for name approval. . . . According to Genprex Chairman and CEO Rodney Varner,
retaining the services of Addison Whitney is an important step in bringing
Oncoprex to market. Obtaining regulatory approval for the proprietary and
non-proprietary drug names is one of the essentials for securing market
approval, he explained. Varner said that he believes that Addison Whitney has
an excellent reputation when it comes to securing such name approvals.”
To view the full article, visit http://ibn.fm/8zRMK
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex immunogene therapy for non-small cell lung cancer.
Genprex’s platform technologies are designed to administer cancer-fighting
genes by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities. Oncoprex has
a multimodal mechanism of action whereby it interrupts cell-signaling pathways
that cause replication and proliferation of cancer cells; re-establishes
pathways for apoptosis, or programmed cell death, in cancer cell;, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is committed
to connecting subscribers with companies that have huge potential to succeed in
the short and long-term future. It is part of our mission statement to help the
investment community discover emerging companies that offer excellent growth
potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment